Trump administration’s Federal Trade Commission launches major investigation into “gender-affirming care” for minors, setting the stage for potential legal action against medical providers making false claims about irreversible treatments for children.
Key Takeaways
- The FTC will host a workshop titled “The Dangers of ‘Gender-Affirming Care’ for Minors” on July 9, 2025, examining potentially unfair or deceptive trade practices
- The workshop follows President Trump’s executive order ending federal support for transgender medical interventions for minors
- Participants will include doctors, medical ethicists, whistleblowers, detransitioners, and parents of detransitioners
- The FTC could take action under Section 5 of the Federal Trade Commission Act if evidence shows medical providers omitted warnings or made false claims
FTC Takes Aim at “Gender-Affirming Care” Industry
The Federal Trade Commission announced a groundbreaking workshop to investigate potentially deceptive trade practices in what some medical providers call “gender-affirming care” for minors. The event, scheduled for July 9, 2025, in Washington, DC, represents the latest step in President Trump’s efforts to protect children from what his administration describes as harmful and irreversible medical interventions. The workshop, officially titled “The Dangers of ‘Gender-Affirming Care’ for Minors,” will bring together medical experts, ethicists, and individuals who have experienced negative outcomes from transgender medical treatments.
The FTC’s investigation stems from concerns that medical providers may be misleading families about the permanence and potential negative effects of interventions like puberty blockers, cross-sex hormones, and surgeries. President Trump’s recent executive order specifically cited medical professionals who “harm children with irreversible interventions under false pretenses” as a key rationale for ending federal support for such treatments. The workshop aims to determine whether consumers have been exposed to false claims and to assess potential harms from these medical practices.
Detransitioners and Whistleblowers to Share Testimony
In a significant departure from previous administrations’ approaches, the FTC workshop will prominently feature individuals who have “detransitioned” – people who once identified as transgender but later reverted to identifying with their biological sex. These individuals, along with parents of detransitioners and medical whistleblowers, will share their experiences with the medical establishment. Their testimony could prove pivotal in determining whether medical providers have engaged in deceptive practices by downplaying risks or exaggerating benefits of transgender interventions for minors.
While in-person attendance at the workshop is by invitation only, the FTC has announced that the entire event will be streamed online to ensure broad accessibility. The public and press can express interest in attending by contacting the commission via email. This approach ensures transparency while allowing the commission to maintain a focused and productive discussion with selected participants who bring relevant expertise or personal experience to the table.
Potential Legal Consequences for Medical Providers
The FTC’s involvement signals potential serious legal consequences for medical providers who may have engaged in deceptive practices. Under Section 5 of the Federal Trade Commission Act, the agency has broad authority to address unfair or deceptive practices in commerce. If the workshop uncovers evidence that medical professionals have omitted warnings about permanent side effects or made false claims about the benefits or reversibility of treatments, the FTC could pursue enforcement actions against providers, hospitals, or pharmaceutical companies involved in transgender medicine for minors.
This initiative represents one component of the Trump administration’s broader effort to protect children from what it considers harmful medical experimentation. The FTC’s consumer protection mission aligns with the President’s directive to ensure that families receive accurate information about medical treatments with life-altering consequences. The commission has emphasized that its investigation will focus on whether medical providers have met their legal obligation to provide truthful information without deception or material omissions.
A Turning Point in Policy
The FTC workshop marks a significant shift in federal policy regarding transgender medical interventions for minors. By bringing together a diverse panel of experts and affected individuals, the commission aims to conduct a thorough examination of the claims made by proponents of “gender-affirming care.” The investigation represents the most substantial federal effort to date to scrutinize an industry that has rapidly expanded in recent years despite growing concerns about long-term outcomes and the quality of informed consent, especially for minors.
Media inquiries about the workshop are being directed to Joe Simonson in the FTC’s Office of Public Affairs, indicating the high level of public interest expected for this groundbreaking investigation. As the workshop date approaches, the commission has promised to release additional details about specific participants and the structure of the discussions, which will likely include examination of medical evidence, marketing practices, and personal testimonies from those affected by transgender medical interventions.
